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The aim of this study was to develop oral lyophilisates with improved meloxicam (MEL) 36 
dissolution, optimizing each step of the preparation by design of experiments. First, meloxicam 37 
nanosuspensions were prepared by high-pressure homogenization (HPH), using PVP, Poloxamer 38 
or PEG as stabilizers and were subjected to freeze-drying using mannitol as cryoprotectant. The 39 
effects of the stabilizers and cryoprotectant were assessed and an optimal formulation was 40 
generated within the design space where the particle sizes and the PDIs are at their lowest values. 41 
The optimal formulation was used at the preparation of oral lyophilisates. Sodium alginate (SA) 42 
and croscarmellose sodium (CCS) were tested as matrix forming agents and three different 43 
freezing regimes were applied. The formulation was optimized, choosing the polymer that yielded 44 
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both high mechanical strength and fast MEL dissolution. Poloxamer led to particle size reduction 45 
down to 10.27% of the initial size, meaning 477.6 ± 7.5 nm, with a slight increase during freeze-46 
drying process. PEG showed lower nanonizing capacity during HPH, but freeze-drying produced 47 
further diminution of the particle size. Since Poloxamer provided advanced size reduction while 48 
preserving MEL crystallinity, it was used for the optimized formulation containing 1% Poloxamer 49 
and 5% mannitol added before freeze-drying. SA showed good structural properties when 50 
compared to CCS and allowed fast MEL dissolution at low ratios. The optimal formulation 51 
contained 1.157% of SA was subjected to thermal treatment during freeze-drying. It disintegrated 52 
in 3.33 sec and released 77.14% of the MEL after 2 minutes. The quality by design (QbD) approach 53 
for the development of pharmaceutical products ensured high quality of the dosage form and good 54 
understanding of the preparation process. 55 
 56 
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1. Introduction 62 
Oral solid dosage forms are preferred by patients for the accurate dosing, their stability, easy of 63 
administration. Still, for the special groups of patients: pediatric, geriatric, patients with disphagia, 64 
their intake imposes serious limitations. The orally disintegrating dosage forms gained attention 65 
from the pharmaceutical industry and academia for their numerous advantages: easy swallowing 66 
without water, pleasant taste, enhancement of patent life cycle and increase of bioavailability of 67 
poorly water soluble drugs (Al Husban et al., 2010, 2011). 68 
In the case of orodispersible tablets (ODTs), bioavailability increases due to the quick 69 
disintegration, followed by dissolution of the active pharmaceutical ingredient (API) in the saliva, 70 
the direct absorption through the oral mucosa to the systemic circulation, bypassing the liver first-71 
pass metabolism (Al Husban et al., 2011). Fast disintegration occurs with highly porous products 72 
obtained either by compressing at low compression forces, molding or by freeze-drying 73 
(Chandraseckhar et al., 2009). Among these methods, freeze-drying provides light, porous 74 
structures that disintegrate in a matter of seconds, “officially” known as oral lyophilisates. 75 
When fast disintegration of the dosage form is granted, bioavailability can be further limited by 76 
the API solubility and dissolution rate (Ghosh et al., 2012, Sarnes et al. 2014). To overcome this 77 
issue, researchers developed solid dispersions, drug-cyclodextrin inclusion complexes and 78 
nanosized particles (Samprasit et al., 2015, Blagden et al., 2007). Particle size reduction to the 79 
nano range with the effective surface area increase showed promising results in terms of 80 
dissolution rate and bioavailability improvement.  81 
From the plethora of APIs being the subject of nanonization, meloxicam is a substance whose 82 
action consists in the selective inhibition of cyclooxigenase-2 isoenzyme and therefore it has 83 
effective anti-inflammatory and analgesic properties (Ochi et al., 2014) that recommend it for both 84 
human and veterinary use (Monteiro et al., 2016). Besides that, it is also emerging as a promising 85 
drug for the treatment of Alzheimer’s disease and cancer. It was categorized into class II of the 86 
Biopharmaceutics Classification System (BCS), meaning it exhibits low water solubility (4.4 87 
µg/ml) and good membrane permeability (Ambrus et al., 2009). Following the intake of classical 88 
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tablets, the peak plasma concentration is reached in 5-6 hours (Dellgado et al., 2014), far too long 89 
for a quick onset of the effect, which motivates the development of a fast dispersible dosage form 90 
with highly soluble meloxicam nanocrystals. 91 
Nanocrystal technologies usually provide sub-micron colloidal dispersions of the drug crystals in 92 
a solvent, which has to be eliminated to obtain the dry powder for the further preparation of a solid 93 
dosage form (Kumar et al., 2015, Lai et al., 2015). One interesting approach is the combination of 94 
nanosuspensions with the production of freeze-dried orodispersible tablets (Lai et al.,2011, 2014). 95 
It involves the nanosuspension preparation and mixing with the matrix forming and cryoprotectant 96 
excipients, followed by freeze-drying, thus obtaining the freeze-dried ODTs. However, the main 97 
issues generated by the preparation of this new dosage form relate to the crystals’ stability before, 98 
after freeze-drying, and to the balance between the disintegration and structure resistance of the 99 
freeze-dried products. The nanosuspensions are thermodynamically unstable systems, which can 100 
be stabilized for a pharmaceutically relevant time by adding surfactants or polymers that act as 101 
stabilizers. A high number of reports acknowledged the stability dependence on the type and 102 
amount of stabilizer, but when freeze-drying process is involved, data about crystal aggregation 103 
tendency is still controversial (Chung et al., 2012). 104 
The design of a new formulation requires complete information about the process parameters and 105 
the way they control the quality attributes. Optimization via empirical screening approach is time 106 
consuming and does not reveal the collective effects of process and formulation factors. Design of 107 
Experiments (DoE) method has been used to overcome these issues by offering a broad 108 
understanding on the relationship between independent and dependent variables. Previous studies 109 
reporting the development of oral lyophilisates containing nanocrystals (Lai et al., 2011, 2014) 110 
used traditional screening approach and focused on API dissolution. They pointed out a complex 111 
preparation process with numerous variables, each one having a potential impact on product 112 
characteristics. Therefore, we believe that a research study conducted by a method that allows their 113 
simultaneous study could add to the knowledge base valuable data.  114 
In this study, a DoE approach was applied to understand and optimize the two important steps in 115 
the preparation of oral lyophilisates (OLs) containing API nanocrystals: nanosuspension 116 
preparation and oral lyophilisates preparation. MEL was used as a model drug due to its emerging 117 
wide clinical applications and to the fact that such formulations of OLs containing MEL 118 
nanoparticles have never been used. In the first step, we established the optimal stabilizer and the 119 
mannitol ratios, after the evaluation of crystal behavior before and after freeze-drying. The second 120 
step focused on the matrix forming agents’ functions and on the freezing regime. We studied their 121 
influence on the mechanical structure and the further on MEL dissolution.  122 
The nanosuspensions were obtained by pre-sonication and high-pressure homogenization, 123 
followed by freeze-drying that led to oral lyophilisates. The particle size, polydispersity index 124 
(PDI) and Zeta potential were investigated as responses in the first step, while in the second 125 
preparation step we evaluated the disintegration time, the texture analysis and the in vitro drug 126 
release.   127 
 128 
2. Materials and methods  129 
 130 
2.1 Materials 131 
The active pharmaceutical ingredient (API) – meloxicam (MEL) was purchased from Unichem 132 
Laboratoires Ltd., India. Mannitol (M) (Pearlitol 200M) and polyethylene glycol 4000 (PEG 4000) 133 
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were purchased from Merck, Germany. PVP K25 (Kollidon 25) and Poloxamer 188 (Polox) 134 
(Kolliphor P188) were kindly donated by BASF, Germany. Croscarmellose sodium (CCS) (Ac-135 
Di-Sol) was obtained from FMC BioPolymer, Belgium and the alginic acid sodium salt (SA) from 136 
Sigma-Aldrich, United Kingdom.  137 
 138 
2.2 Methods 139 
 140 
2.2.1 Nanosuspension optimization 141 
2.2.1.1 Design of experiment 142 
Previous research in nanosuspension preparation revealed the importance of the stabilizer type and 143 
concentration for the API dissolution behavior. The stabilizers should assure wetting of the 144 
hydrophobic surfaces and increase of the activation energy of the agglomeration process, therefore 145 
be a barrier to agglomeration (Van Eerdenbrugh et al., 2008). The type of stabilizer was set as 146 
qualitative variable (X1). We chose two polymers: PVP, PEG and one nonionic surfactant, Polox. 147 
Their weight concentrations in volume were varied on three levels: 0.25 – 1 – 1.75% (w/V) (X2). 148 
During the freeze-drying, a cryoprotectant was added to avoid freeze damage due to ice formation 149 
and particle aggregation (Wang et al. 2013). We chose mannitol as cryoprotectant, at 150 
concentrations comprised between 0 and 5% (X3). The effects of the aforementioned parameters 151 
on the crystal size, polydispersity (PDI) and Zeta potential were investigated using a three-factor, 152 
three-level DoE.   153 
The critical quality attributes (CQAs) of the nanosuspensions were the average particle size and 154 
the MEL crystallinity. 155 
 As responses, we chose the particle size and PDI after the size reduction (Y1, Y2) and 156 
after the freeze-drying (Y3, Y4). In order to assess the size and PDI variations produced by freeze-157 
drying process only and test if they have any statistical significance within the DoE, we calculated 158 
the size and PDI changes from the following equations: 159 
    Size variation (Y5) = (initial size – final size)*100/initial size 160 
                        PDI variation (Y6) = (initial PDI – final PDI)*100/initial PDI. 161 
 The DoE modeling was performed using Modde 10.0 (Umetrics, Sweden) software and 162 
was used to provide a surface model for the six mentioned responses and an optimized formulation 163 
to take forward to the second step of the study. 164 
  165 
2.2.1.2 Preparation of nanosuspensions   166 
The micronized MEL (with 4.51 ± 0.57 µm average size and polydispersity index equal to 1) was 167 
suspended in the aqueous stabilizer (PVP, Polox or PEG) solution, using a magnetic stirrer to a 168 
concentration of 0.75% (w/V). The suspensions were stirred for 10 minutes at 1000 rpm. Each of 169 
them was then sonicated for 10 minutes at 70% amplitude using a high power ultrasound device 170 
(Hielscher UP 200S Ultrasonic processor, Germany) to wet the drug. Further size reduction to 171 
nanorange was achieved by applying high-pressure homogenization (HPH) with an Emulsiflex C5 172 
apparatus (Avestin, Ottawa, Canada). 2 cycles at 500 bar were applied, followed by 20 cycles at 173 
1000 bar. 174 
 175 
2.2.1.3 Freeze-drying of nanosuspensions 176 
MEL nanosuspensions were freeze-dried using a lab scale VirTis Advantage Plus freeze-drier (SP 177 
Scientific, Gardiner, USA). Briefly, four 0.5ml samples were taken from each of the 178 
nanosuspensions and poured into blister sockets. The blisters were placed on the freeze-dryer shelf 179 
and cooled to -50°C at a rate of 1°C/minute, thus we applied a fast freezing regime. The 180 
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temperature was kept constant for 6 hours for complete product solidification. The primary drying 181 
was performed at -20°C for 20 hours and vacuum of 0.2 mbar, followed by secondary drying at 182 
5°C for 6 hours at 0.2 mbar. 183 
 184 
2.2.1.4 Particle size analysis 185 
Particle size measurements were performed by photon correlation spectroscopy (PCS) using a 186 
Zetasizer Nano ZS90 (Malvern Instruments, UK). Both the nanosuspensions before freeze-drying 187 
and the freeze-dried nanocrystals were subjected to this measurement. A mean particle diameter 188 
at an angle of 90° and a constant temperature of 25°C and the width of the size distribution (PDI) 189 
were determined by this method. 0.5ml of the suspension or corresponding freeze-dried product 190 
were diluted to 15ml with purified water. All samples were subjected to 60s of sonication prior to 191 
the size analysis in order to disperse the aggregates if present. Zeta potential was determined using 192 
the same equipment, by estimating the particle electrophoretic mobility in a thermostated cell. The 193 
results are presented as mean of three determinations and standard deviation. 194 
 195 
2.2.2. Oral lyophilisates optimization 196 
2.2.2.1. Experimental design 197 
The optimal nanosuspension formulation revealed by the first DoE (containing 7.5 mg MEL/ml, 198 
1% (w/V) Polox and 5% (w/V) mannitol) was taken forward to the next step, the formulation and 199 
optimization of the oral lyophilisates. Once the nanosuspension characteristics were established, 200 
we identified other factors that could influence the quality profile of the OLs: the type and content 201 
of matrix forming agent and the freezing rate. The chosen matrix forming agents (X1) were sodium 202 
croscarmellose (CCS) at a ratio of 1%, 3% or 5% and sodium alginate (SA) at a ratio of 1%, 2% 203 
or 3%. The matrix forming agent percentages (X2) were chosen from viscosity studies (results 204 
not shown); the viscosity had to be high enough to maintain suspension stability and still the 205 
suspensions had to be fluid enough to be accurately poured into blister sockets. The CCS 206 
percentages, of 1%, 3% and 5% were chosen from previous viscosity measurements that ranged 207 
between 40 and 250 mPa s, while for the sodium alginate, the viscosities of the 1%, 2% and 3% 208 
dispersions varied from 200 to 2000 mPa s. These dispersions were considered to be consistent 209 
enough to maintain meloxicam stability before freezing, but still fluid enough to be accurately 210 
poured into the blister sockets. The third independent variable was the freezing type: fast, slow 211 
or annealing (X3).  212 
 The CQAs of OLs were the disintegration time, the mechanical strength and the MEL 213 
dissolution profile. 214 
 Several evaluation methods were selected in order to monitor the CQAs and their results 215 
were set as responses within the DoE. Therefore, we measured the disintegration time (Y1), the 216 
hardness (Y2), the fracturability (Y3), the % of dissolved MEL after 2 minutes (Y4), 4 minutes 217 
(Y5), 6 minutes (Y6), 12 minutes (Y7), 18 minutes (Y8) and 30 minutes (Y9). 218 
 The same software was used to test the model and obtain the optimized formulation. 219 
 220 
2.2.2.2. Preparation of oral lyophilisates 221 
The previously optimized nanosuspension (containing 7.5 mg MEL/ml, 1% (w/V) Polox and 5% 222 
(w/V) mannitol) was prepared according to the described methods (2.2.1.2.). For each of the OL 223 
formulations, the corresponding matrix forming agent was added in the indicated ratio and the 224 
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formed viscous suspension was kept under gentle stirring until the complete polymer dispersion 225 
and homogenization. 226 
0.5 ml of the obtained suspension that contained 3.75 mg MEL was poured into 30 blister sockets 227 
(blister material: PVC-Aclar®, PCTFE, poly-chloro-tri-fluoro-ethylene, cavity sizes: 12.70 mm 228 
diameter x 5.50 mm depth) and freeze-dried (VirTis Advantage Plus, SP Scientific, Gardiner, 229 
USA). The freeze-drying cycle started with one of the three proposed freezing profile (fast, slow 230 
or annealing), followed by primary drying at -20°C for 20 hours and vacuum of 0.2 mbar and by 231 
secondary drying at 5°C for 6 hours at 0.2 mbar (Fig. 1). 232 
 233 
Figure 1 234 
 235 
Fig. 2 illustrates the graphical procedure comprising the complete OL preparation process. 236 
 237 
Figure 2 238 
 239 
2.2.2.3. Characterization of oral lyophilisates 240 
 241 
The disintegration time was measured according to Eur. Pharm. 8.0 method, by placing an oral 242 
lyophilisate in 200ml distilled water kept at 20 ± 0.5°C. The time necessary for complete 243 
disintegration, until no solid residue was perceived, was recorded using a digital stopwatch. The 244 
average disintegration time and the standard deviation of six tested tablets were calculated. 245 
 246 
The texture analysis was performed using Brookfield TexturePro CT V1.5 (Brookfield 247 
Engineering, USA). Tablets were extracted from the alveolae, placed on a horizontal rigid surface 248 
and subjected to constant pressure. Pressure was applied by an acrylic probe (TA10), to a constant 249 
deformation of 80%, at a test speed of 0.1mm/s and a load of 10 g. Load vs. distance curves were 250 
recorded using Texture Pro Software. For each of the formulations, three measurements were 251 
carried out for the average hardness at 1.6 mm, fracturability and their corresponding standard 252 
deviations were calculated. The fracturability, as well as the hardness, derives from the texture 253 
calculations. The analyzer measured the resistance of the sample to the advance of the acrylic 254 
probe with a constant speed. The fracturability is calculated as the load value at the first fracture. 255 
A fracture is a sudden load drop that indicates an abrupt resistance decrease in the sample. Low 256 
fracturability values are correlated to brittle products. If no fracture occurs during the compression 257 
cycle, the fracturability value equals the hardness value. The fracturability was determined for 258 
three samples from each formulation; the mean value and the standard deviation were calculated. 259 
 260 
The in vitro dissolution test was performed according to the Eur.Pharm. 8.0, using the paddle 261 
method. 900 ml of phosphate buffer with pH 7.4 at 37°C were used as dissolution media, at a 262 
rotating speed of 50 rpm. At certain time intervals, 5 ml samples were withdrawn, filtered through 263 
0.2 µm cellulose filters (Phenomenex Syringe filters) and analyzed spectrophotometrically at 360 264 
nm (Jasco V-560 UV-VIS, Easton, USA) against phosphate buffer pH 7.4 as a blank. Every sample 265 
was replaced with the same volume of the fresh media. The experiment was done in triplicate and 266 
the average meloxicam release at each sampling time and their standard deviations were 267 
calculated. 268 
 269 




2.2.3.1. X-ray powder diffraction (XRPD) 272 
The physical state of MEL in the different stages of the preparation process (for raw MEL and the 273 
freeze-dried nanosuspensions) was evaluated by XRPD. XRPD spectra were recorded with a 274 
BRUKER D8 Advance X-ray diffractometer (Bruker AXS GmbH, Karlsruhe, Germany) system 275 
with Cu Ká1 radiation (ë = 1.5406 Ĺ) over the interval 5-30°/2. The measurement conditions were 276 
as follows: target, Cu; filter, Ni; voltage, 40 kV; current, 40 mA; time constant, 0.1 s; angular step 277 
0.010. In the determination of the degree of crystallinity, the total area of the characteristic three 278 
peaks with largest intensity was examined, after smoothing and background removal.  279 
 280 
2.2.3.2. Scanning electron microscopy (SEM) 281 
The morphology of the raw MEL, nanocrystals dried at room temperature without cryoprotectant 282 
and freeze-dried products was examined by SEM (Hitachi S4700, Hitachi Scientific Ltd., Tokyo, 283 
Japan). A sputter coating apparatus (Bio-Rad SC 502, VG Microtech, Uckfield, UK) was applied 284 
to induce electric conductivity on the surface of the samples. The air pressure was 1.3-13.0 mPa.  285 
 286 
3. Results and discussion 287 
  288 
3.1. Optimization of nanosuspension 289 
3.1.1. Experimental design 290 
In order to achieve an optimal pharmaceutical product, all the possible variables that may influence 291 
the characteristics of the product should be studied in detail. Two types of variables are involved 292 
in the development procedure: formulation and process variables. In this study, we chose to focus 293 
on the formulation parameters, while maintaining the process and its parameters at a constant level. 294 
The preparation of nanosuspensions via high-pressure homogenization (HPH) offers a set of 295 
advantages over the other size reduction methods, including low processing time, narrow size 296 
distribution and few contamination sources (Wang et al., 2013). Moreover, the organic solvents 297 
are not necessary, thus it is also ecologically friendly. Furthermore, HPH does not induce crystal 298 
form transformation, which could relate to higher drug and dosage form stability (Wang et al., 299 
2013). 300 
In this study, US preceded HPH, in order to disperse the eventual drug agglomerates and increase 301 
the initial contact between the drug and the stabilizer. A constant number of HPH cycles was 302 
chosen for each of the suspensions, at low pressure for the beginning and then at high pressure. 303 
As stabilizers, we chose two polymers (PVP and PEG) and a nonionic surfactant (Polox). PVP 304 
was previously used as an agglomeration inhibitor at the preparation of MEL microparticles and 305 
nanocrystals (Pomazi et al., 2013, Bartos et al., 2015). In a grinding procedure to obtain MEL 306 
nanocrystals, both PVP and PEG were used as stabilizers and were reported to significantly 307 
improve the API dissolution rate (Kurti et al., 2011). Polox was confirmed as one of the most 308 
efficient stabilizers with respect to the achieved size reduction, size distribution but also 309 
concerning the morphology and aggregation capacity (Wang et al., 2013). Its high solubilizing 310 
capacity was another reason for selecting it as excipient (Mata et al, 2005).  311 
For the freeze-drying process, mannitol (M) was chosen as a cryoprotectant for its ability to dispose 312 
between the nanocrystals in the cryoconcentrated product, to prevent aggregation and increase the 313 
structure strength.    314 
Based on preliminary experiments and literature data, the stabilizers (X1), their ratios (X2) and the 315 




factorial design for MEL nanosuspension formulation. To evaluate the nanosuspensions’ behavior 317 
through the preparation process and through freeze-drying, we chose to measure the size and PDI 318 
after HPH (Y1, Y2), then after freeze-drying and reconstitution (Y3, Y4) and the size and PDI 319 
variation caused by freeze-drying (Y5, Y6) (see Supplementary material, Table 1).  320 
 321 
Table 1 322 
 323 
Multiple linear regression analysis and ANOVA were used to develop a mathematical model for 324 
each response. Equation 1 represents the general form of each model: 325 
Y =  B0 + B1X1 + B2X2 + B3X3 + B4X1
2 + B5X2
2 + B6X3
2 + B7X1X2 + B8X1X3 + B9X3X2 + B10X1X2X3  326 
            (eq.1),  327 
where Y is the dependent variable (response), B0 is the mean response (intercept) and Bi are 328 
regression coefficients derived from the obtained experimental values. X1, X2, X3 are individual 329 
effects; they represent the result of the variation of one factor, while keeping the other factors at a 330 
constant value.  X1
2, X2
2 and X3
2 are quadratic effects that indicate non-linear correlations with the 331 
response. X1X2, X3X2, X1X3 and X1X2X3 are interaction effects which reveal the variations of the 332 
responses when 2 or more factors change simultaneously. 333 
The revised values obtained for eq. 1 regression coefficients are listed in Table 1 for each of the 334 
responses, together with their statistical significance, expressed as p-value. The coefficients 335 
indicate the magnitude of the effect of each of the independent variables and the way in which the 336 
factors influence the responses is given by + sign for positive influence, or – sign for negative 337 
influence. It was observed that all chosen factors produced significant changes with the responses. 338 
The regression coefficient R2 was above 0.90 for responses Y1, Y2, Y3 and Y5, 0.89 for Y4 and 0.74 339 
for Y6, which demonstrates the good fit of the data to the created model. When the size and PDI 340 
were measured after HPH, the critical factors were the stabilizer type and ratio (p < 0.05). After 341 
FD, the M ratio became the third critical factor. Two-way interactions between the type of 342 
stabilizer /its concentration and after FD between the stabilizer concentration/ M ratio had a 343 
significant influence on the nanocrystal size and PDI. 344 
 345 
Table 1 346 
 347 
3.1.2. The average size and PDI after HPH (Y1, Y2) 348 
The average sizes after HPH ranged between 477.6 nm and 1232.0 nm, with PDIs between 0.29 349 
and 0.88. The lowest particle size was met with the PVP and Polox, while the sizes reached after 350 
the same procedure using PEG as a stabilizer led to high values up to 1.2 µm. The wide data 351 
variations indicate the strong influence of the selected factors on the dependent variables. The 352 
regression coefficients listed in Table 1 pointed out the way stabilizers influence the nanocrystal 353 
formation. It seems that PVP caused the average size decrease, but the interactive effect between 354 
the type of stabilizer and its ratio indicates the opposite, a positive effect on the size. The response 355 
surface helps further understanding on this subject showing that up to 1.3 %, PVP generates MEL 356 
size reduction, while upper ratios hold back the nanonization process. Similarly, the PDI decreased 357 
up to 1% PVP and at higher concentrations it increased again. PEG produced the lowest size 358 
decrease, down to a minimum of 854 nm.  The high viscosity polymers create in the suspension 359 
could be the reason for the impaired size reduction at high levels (Patel et al., 2014), due to the 360 
homogenization process hindering. Polox caused the most abrupt size and PDI decrease and kept 361 
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its behavior even at high ratios, as indicated by the response surfaces in Fig.3. 1% Polox led to the 362 
lowest crystal size of 477.6 nm and the corresponding PDI of 0.34. 363 
 364 
3.1.3. The average size and PDI after FD (Y3, Y4) 365 
The size and the PDI after FD were measured to assess the influence of independent variables on 366 
the global process. After HPH, M was dissolved in the obtained nanosuspensions, therefore its 367 
effect became visible in the statistical data. The average particle sizes ranged between 489.5 nm 368 
and 836.1 nm, so the upper limit decreased during FD. The results (Table 1) showed that PVP ratio 369 
did not have a significant influence on the size, but its presence determined a high PDI. Polox 370 
yielded low crystal sizes with no change of polydispersity degree (Fig. 3), while PEG determined 371 
the lower size reduction and wide size distribution.  372 
M displayed a significant negative effect on both average crystal size and PDI, because it prevented 373 
aggregation in the cryoconcentrated system.  374 
 375 
Figure 3 376 
 377 
3.1.4. The size and PDI variations caused by freeze-drying 378 
For a statistical evaluation of the crystal size and PDI variations induced selectively by the freeze-379 
drying process, we calculated the percentages of size and PDI increase/decrease and tested them 380 
as responses in the experimental design (see Supplementary material, Table 1). 381 
Apparently, for most of the freeze-dried nanosuspensions, the crystal size decreased (14 out of 19). 382 
The regression coefficients indicate which of the formulation factors influence the variation and 383 
how (Table 1). An individual positive effect for PVP as stabilizer was obtained, meaning that at 384 
low concentrations, PVP determined the size increase during FD. If the PVP ratio is too low, it is 385 
possible that it does not cover the entire particle surface by adsorption (Wang et al., 2013). 386 
Therefore, the uncovered sides of MEL particles could exhibit aggregation capacity and lead to 387 
average size increase. An interactive negative effect between PVP as stabilizer and the stabilizer 388 
concentration showed that high PVP content led to size reduction during FD, which confirms the 389 
previous hypothesis. According to the statistical data, Polox had a positive effect on crystal sizes, 390 
along the entire concentration range. On the opposite, freeze-drying nanosuspensions with PEG as 391 
stabilizer determined a significant particle size decrease. As PEG is highly hydrophilic, it could 392 
adsorb water by hydrogen bonding and the freezing water molecules could break the stabilized 393 
conglomerates into smaller particles. 394 
M was added to the system when size reduction process was finished, therefore we expected it to 395 
prevent aggregation and not to decrease the average size below the initial values. Surprisingly, the 396 
sizes decreased even further. The explanation could be that M solution penetrated into the particle 397 
fissures and when M crystallized during FD, the volume increase generated cracks into the crystal 398 
aggregates with consequent size reduction. 399 
  400 
3.1.5. The  Zeta potential 401 
The Zeta potential is a parameter that indicates the stability of nanosuspensions with values 402 
between -100 mV and 100 mV. Products with Zeta potentials in the range [-25mV; 25mV] are 403 
considered less stable, with high agglomeration probability. The values we obtained after HPH 404 
ranged between -35.6 mV and -20.1 mV and suggest good stability for most of the 405 
nanosuspensions (results not shown). 406 
 407 




SEM analysis 410 
The SEM images with reduced size MEL containing the same amount of stabilizer (1%), showed 411 
the changes in the appearance and morphology of the obtained nanoparticles (Fig. 4). The large 412 
raw MEL crystals (A) presented regular prismatic shape with smooth surfaces. The particle size 413 
reduced, regardless of the type of stabilizer (B-D). PVP softened and covered the MEL particles 414 
(Martha et al., 2013) that kept their shapes within an amorphous conglomerate (B). The 415 
aggregation tendency of the MEL-PVP particles is visible in the SEM captions.  416 
Polox as stabilizer led to oval shaped individual crystals (C) with soft edges that could be attributed 417 
to erosion phenomena during the homogenization process. Partial dissolution of Mel crystals 418 
mediated by Polox could also be incriminated, but since Polox critical micelle concentration is 419 
higher than the ones used in our study (between 24 and 32 mg/ml according to Moghimi et al., 420 
2004), mechanical softening of crystal edges is more probable. The analyzed sample showed good 421 
size uniformity, also confirmed by PCS. 422 
PEG particles preserved their sharp edges, but they had a wide size distribution and the size 423 
reduction did not reach the level of the other two stabilizers. 424 
 425 
Figure 4 426 
 427 
XRPD analysis  428 
X-ray powder diffraction was performed for raw MEL and the freeze-dried nanosuspensions 429 
prepared according to the experimental design. It was meant to assess the crystalline changes that 430 
MEL might have suffered during the HPH and freeze-drying processes. The diffractogram of raw 431 
MEL exhibits numerous distinct peaks, at diffraction angles 2Ɵ of 13.22, 15.06 and 26.46 (Kurti 432 
et al., 2011), which confirm its initial crystallinity. Fig. 5 shows the diffractograms of the freeze-433 
dried nanosuspensions and the changes that appear with different types and ratios of stabilizers. 434 
For the sample with low PVP content (N8), the MEL characteristic peaks can be observed, but at 435 
high PVP ratios the areas under the peaks considerably diminished (N11, N13), revealing the 436 
amorphous structure of the nanoparticles. The products samples containing Polox as stabilizer 437 
displayed all the MEL characteristic peaks at all concentration levels of the stabilizer, which 438 
indicates that the crystalline state was preserved (N9, N12, N13). The PEG freeze-dried 439 
nanosuspensions exhibited partial loss of crystallinity at low PEG concentrations (N15) (Martha 440 
et al., 2013). 441 
 442 
Figure 5 443 
 444 
3.1.7. Optimization of nanosuspension 445 
Based on the revised equations and surface response plots, the software was used to generate the 446 
set of conditions/ optimum formulation variables in order to obtain the nanosuspensions with 447 
desired CQA profile. The selected criterions were to minimize the average sizes and PDI after 448 
HPH and after freeze-drying and to have a crystalline product. The software generated the 449 
following conditions: Polox as stabilizer at 1% ratio and 5% M as cryoprotectant during freeze-450 
drying. Through statistical analysis, from the initial experimental area, a Design Space was 451 
identified (Figure 6), where all the conditions imposed to the nanosuspensions formulations would 452 
be fulfilled at a specified risk level. Each point from the Design Space represents a nanosuspension 453 
formulation obtained with a risk level expressed as Defect per one Million Opportunities (DPMO). 454 
The green areas could deliver a series of formulations that would comply to the conditions of low 455 
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average size and PDI, with a probability of 99.95%.The optimal nanosuspension was obtained 456 
using the indicated parameters and the same procedure: the US, HPH and freeze-drying regimes 457 
applied during the initial experiments. It exhibited a Zeta potential of -28.31 ± 0.48 mV, therefore 458 
good stability. The characterization of the optimal formulation compared to the predicted values 459 
and the calculated residuals are presented in Table 2. The closeness between the experimental and 460 
the predicted results confirmed the validity of the statistical model and its predictive power. The 461 
optimal suspension evaluated in Table 2 contains 7.5 mg MEL/ml, 1% (w/V) Polox 188 and 5% 462 
(w/V) M. 463 
 464 
Figure 6 465 
 466 
Table 2 467 
 468 
 469 
3.2. Optimization of oral lyophilisates 470 
 471 
3.2.1. Design of experiment 472 
The optimal nanosuspension was taken forward to the next step, an experimental design for the 473 
optimization of oral lyophilisates. At this stage, the CQAs are disintegration time, mechanical 474 
strength and MEL dissolution which is granted by the size reduction achieved in the first step 475 
(Mauludin et al., 2009). A thorough study of the formulation factors is necessary in order to 476 
balance the quick disintegration time and the high mechanical strength. Both disintegration time 477 
and mechanical strength are conditioned by the type and ratio of matrix forming agents, while the 478 
structure depends on the freezing rate (Harnkarnsujarit et al., 2012). 479 
As matrix forming agents we chose CCS, superdisintegrant used for its high hydrating and swelling 480 
capacity that grants suspension stability up to the freezing step. Moreover, it was mentioned for 481 
the ability to increase API dissolution (Lai et al., 2014). SA was selected for its capacity to yield 482 
highly viscous dispersions at low polymer concentrations (Vicini et al., 2015). The concentration 483 
levels were chosen from previous viscosity studies (results not shown) so that the dispersions 484 
would be fluid enough to be poured into blister sockets and viscous enough to prevent settling 485 
phenomena: 1-3-5% for CCS and 1-2-3% for SA. 486 
During the lyophilization process, the freezing step is of high importance due to the crystallization 487 
processes that further impact the texture of the frozen matrix and the morphological characteristics 488 
of the dried cake. For orally disintegrating dosage forms, slow freezing is more appropriate due to 489 
the formation of structures with large pores, easily disintegrating upon hydration. Large pores 490 
promote disintegration, but when it comes to systems containing suspended nanocrystals, a dense 491 
cryoconcentrated phase during freezing could induce aggregation phenomena. Therefore, we 492 
planned to study the influence of two different freezing rates: 0.5°/minute decrease (slow freezing), 493 
1°/minute decrease (fast freezing) (Fig. 1). An annealing step was also considered for its reported 494 
benefits on size distribution of ice crystals, on accelerating primary drying and reducing 495 
heterogeneity between samples (Abdelwahed et al., 2006). Moreover, mannitol as bulking agent 496 
is known to yield a mixture of amorphous and crystalline forms (Kim et al. 1998, Torrado et al., 497 
2002) especially at low mannitol ratios, therefore an annealing step integrated into the freezing 498 
phase could maximize its crystallization (Mehta et al., 2013). The aforementioned independent 499 
variables were included in a quadratic D-Optimal design: the type of matrix forming agent (X1), 500 
the matrix forming agent ratio (X2) and the freezing rate (X3). As responses, we chose the 501 
disintegration time (Y1), the hardness (Y2), the fracturability (Y3) and the percentage of dissolved 502 
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MEL at 2 minutes (Y4), 4 minutes (Y5), 6 minutes (Y6), 12 minutes (Y7), 18 minutes (Y8) and 30 503 
minutes (Y9). For the evaluation of the results (listed in Supplementary material, Table 2), multiple 504 
linear regression and ANOVA test were applied. They showed high variability, which indicates a 505 
strong dependence on the selected independent factors. A model was developed for each response, 506 
expressed as an equation of the response as a function of the independent variables and their 507 
interactions (eq. 1, 3.1.1.).  508 
The statistical analysis showed that all the selected independent variables had a significant 509 
influence on the responses. R2 was above 0.9 for responses Y1, Y3, Y4, Y5 and Y6 and between 0.8 510 
and 0.9 for Y2, Y7, Y8 and Y9, meaning that more that 80% of the responses variability was 511 
explained by the model.  512 
 513 
Table 4 514 
  515 
3.2.2. The disintegration time (Y1) 516 
The OLs disintegrated between 0.83 and 58 s, as shown in Table 4. The results proved that the 517 
type of matrix forming agent (X1), its ratio (X2) and the freezing rate (X3) significantly influenced 518 
the disintegration time (Fig. 7). As expected, high CCS content determined a fast disintegration, 519 
while high SA percentages led to slowly disintegrating OLs. The type of freezing also influenced 520 
the disintegration: annealing decreased the disintegration time, while progressive freezing delayed 521 
it. An interactive effect was noticed between the matrix forming agent (MFA) content and the type 522 
of freezing: when annealing, the higher the MFA content, lower the disintegration time. On the 523 
contrary, if progressive freezing was applied on highly concentrated MFA dispersions, 524 
disintegration was delayed. Disintegration depends on the structure of the 3D freeze-dried matrix. 525 
Annealing procedure allows the rearrangement of crystals with the structure relaxation; therefore, 526 
it usually leads to highly porous products, easily permeated by the dissolution media. 527 
 528 
Figure 7 529 
 530 
3.2.3. The texture analysis 531 
The OLs were completely dry freeze-dried matrices, with the diameter of 12.75 ± 0.15 mm and 532 
the height of 5.14 ± 0.18 mm. The texture analysis revealed the OL’s behavior when being 533 
subjected to constant pressure. It yielded two parameters: the hardness (Y2) and the fracturability 534 
(Y3), which describe the mechanical properties of the structures.  The two MFA yielded quite 535 
different products. The OLs with CCS were extremely soft and fragile, while the OLs containing 536 
SA gave firm and stiff structures, easy to extract from the blister sockets. Therefore, the only 537 
significant influence was assessed with the MFA variation: CCS determined hardness decrease, 538 
while SA determined the hardness increase, with no significant influence from their ratios (Fig.8 539 
A).  540 
Fracturability is an indirect indicator of the brittleness of a product and is calculated as the load 541 
value at the first fracture, more precisely, it shows the resistance of a product to fractures. The 542 
influence of the MFAs was, as expected, the most important: SA gave high fracturability, while 543 
CCS gave low fracturability and their ratio increase determined higher fracture resistance in both 544 
cases (Fig. 8B). 545 
 546 




The mechanical profile of the oral lyophilisates was represented as load (N) vs. distance (mm) 549 
curves (Fig. 9) and clearly shows the differences between CCS and SA behavior as structural 550 
excipients. The weak CCS matrix appears like a very heterogeneous porous structure with thin, 551 
disrupted pore walls. As for the suspensions containing SA, the dehydration led to a highly porous 552 
structure, with big cavities produced by water crystals sublimation, but with slightly thicker pore 553 
walls, linked to each other. 554 
 555 
Figure 9 556 
 557 
Interestingly, the type of freezing had no significant effect on the product’s hardness or 558 
fracturability parameters (Fig. 8) when analyzed within the experimental design, but a closer 559 
texture curve analysis (results not shown) shows that progressive freezing yields weak mechanical 560 
profiles as compared to the other freezing treatments.  561 
 562 
3.2.4. In vitro dissolution test 563 
The drug release from the lyophilized matrix was assessed by in vitro dissolution studies. 564 
Dissolution is a limiting factor for the oral absorption and thus for the pharmacological effect. In 565 
this study, the dissolution profiles were studied on a 30 minutes range, in PBS pH 7.4. 566 
After 2 minutes, the ratio of dissolved MEL ranged between 21.57% and 100%. The wide range 567 
shows the strong influence of independent variables on the responses. The influences of 568 
independent variables on the dissolution profile were constant at all the tested times. MEL 569 
dissolution was favored by the presence of CCS and delayed by SA. The higher the CCS ratio, 570 
more MEL was dissolved. On the contrary, at high SA ratios, the dissolution percentages 571 
decreased. The freezing rate influenced the dissolution profile during the first 6 minutes of the test; 572 
after 6 minutes, more than 90% of MEL was dissolved for 15 formulations out of 21.  573 
The sudden freezing delayed the dissolution, while the progressive freezing and the annealing 574 
seemed to have a less significant enhancing effect on dissolution. The faster dissolution caused by 575 
slow freezing could be a consequence of the weak mechanical strength it delivers and the higher 576 
porosity produced by ice crystal growth in the freezing phase (Iurian et al., 2016). 577 
 578 
Figure 10 579 
 580 
3.2.5. Optimization of oral lyophilisates 581 
The statistical calculations and experimental observations led to an accurate knowledge of the 582 
variables that influence OL’s characteristics. MEL dissolution was granted by its size reduction, 583 
while the OL’s disintegration and mechanical properties were controlled by the MFA type and 584 
ratio and by the freezing regime. The statistics software was used to generate the optimal OL 585 
formulation, by applying a set of constraints. We chose to minimize the disintegration time and 586 
maximize the mechanical strength and MEL dissolution after 2, 4 and 6 minutes. The software 587 
indicated the optimal formulation with SA as MFA, at -0.843 concentration level, meaning 1.157% 588 
SA and being subjected to annealing as a thermal treatment before freeze-drying. 589 
The optimal OLs were prepared and tested following the same techniques as the previous 590 
formulations using the independent variables that resulted from the experimental design analysis. 591 
The optimal formulation characterization is listed in Table 3. All the responses were in the 592 
predicted range, therefore the experimental design was considered valid and could be further used 593 
for the development of oral lyophilisates with desired characteristics. 594 
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Table 3 595 
4. Conclusion 596 
The study reveals a two steps QbD strategy for the development of oral lyophilisates with high 597 
drug bioavailability. The first stage handles the development of an optimal nanosuspension with 598 
respect to the crystal size and PDI, with focus on the changes brought by freeze-drying process 599 
and how do different factors influence those changes. The optimal formulation that achieved the 600 
lowest average size and PDI both before and after freeze-drying contained 1% Polox as stabilizer 601 
and was submitted to lyophilization having 5% M as cryoprotectant. It was included in the second 602 
step of the study for oral lyophilisates optimization, when three more variables were added: the 603 
matrix forming agent type, ratio and the freezing regime. Sodium alginate granted high structural 604 
stability but also fast disintegration and drug dissolution, therefore it was selected as matrix 605 
forming agent in the optimal formulation.  606 
The experimental design approach was a valuable tool for the thorough study of variables 607 
influencing the nanosuspension and oral lyophilisate preparation. Creating such models offers high 608 
versatility; the two validated experimental designs could be further used together for the 609 
preparation of oral lyophilisates or separately as basis for other research studies. The optimal oral 610 
lyophilisates according to Table 3 contain: 3.75 mg MEL/OL, 5 mg Polox 188/OL, 25 mg 611 
mannitol/OL and 5.78 mg Sodium Alginate/OL, obtained from the freeze-drying a suspension that 612 
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 The revised quantitative factor effects and associated p values for the responses 
Term 
Size after HPH 
 (Y1) 
PDI after HPH 
 (Y2) 
Size after FD 
 (Y3) 
PDI after FD  
(Y4) 
Size variation after 
FD (Y5) 
PDI variation after FD 
(Y6) 
Constant 681.437 (0.000) -0.429 (0.000) 2.770 (0.000) -0.472 (0.000) -11.168 (0.000) -41.753 (0.000) 
X1 PVP -76.058 (0.000) -0.071 (0.000) -0.007 (0.471) 0.031 (0.087) 5.329 (0.002) 7.205 (0.000) 
X1 Poloxamer -138.297 (0.000) -0.059 (0.000) -0.037 (0.002) -0.072 (0.000) 8.854 (0.000) -0.344 (0.000) 
X1 PEG 214.355  (0.000) 0.130 (0.000) 0.044 (0.001) 0.040 (0.037) -14.184 (0.000) -6.860 (0.000) 
X2 106.637 (0.000) 0.058 (0.000) 0.005 (0.593) -0.062 (0.006) -9.267 (0.000) -6.906 (0.000) 
X3 3.470 (0.804) -0.000 (0.916) -0.025 (0.008) -0.008 (0.102) -4.603 (0.002) -2.035 (0.002) 
X2*X2 90.858 (0.017) 0.129 (0.000) 0.037 (0.068) - - 7.695 (0.000) 
X1 PVP*X2 54.710 (0.007) -0.008 (0.375) 0.019 (0.072) - -7.576 (0.000) - 
X1 Poloxamer *X2 -114.159 (0.000) -0.027 (0.012) -0.048 (0.000) - 4.927 (0.005) - 
X1 PEG *X2 59.449 (0.004) 0.035 (0.008) 0.029 (0.010) - 2.649 (0.088) - 
X2*X3 - - 0.026 (0.007) 0.057 (0.003) 5.574 (0.000) 7.658 (0.002) 
















 Optimal nanosuspension formulation results 
 Experimental values Predicted values Residual 
Size after HPH (nm) 463.5 ± 9.71 453 10.5 
PDI after HPH 0.312 ± 0.014 0.302 0.01 
Size after Freeze-drying (nm) 501.7 ± 9.18 491 10.7 






















Optimal oral lyophilisate formulation results 
 Experimental values Predicted values Residual 
Disintegration time (s) 3.33 ± 0.76 1.89 1.44 
Hardness (N) 16.34 ± 0.48 16.10 0.24 
Fracturability (N) 22.58 ± 4.36 21.19 1.38 
% of dissolved Mel after 2 minutes 77.14 ± 6.55 71.79 5.34 
% of dissolved Mel after 4 minutes 86.82 ± 8.64 93.77 -6.95 
% of dissolved Mel after 6 minutes 96.71 ± 4.11 100.41 -3.70 
 
